159 related articles for article (PubMed ID: 10760430)
41. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
42. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer.
Schild SE; Wong WW; Vora SA; Halyard MY; Wheeler RH
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):729-34. PubMed ID: 12377324
[TBL] [Abstract][Full Text] [Related]
43. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
44. Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.
Beitler JJ; Anderson P; Haynes H; Sood B; Fields A; Goldberg G; Vikram B; Runowicz CD; Wadler S
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):637-42. PubMed ID: 11849784
[TBL] [Abstract][Full Text] [Related]
45. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
46. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
47. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer.
Suzuki M; Nishimura Y; Nakamatsu K; Kanamori S; Koike R; Kawamoto M; Mori K
Jpn J Clin Oncol; 2003 Jun; 33(6):297-301. PubMed ID: 12913084
[TBL] [Abstract][Full Text] [Related]
49. Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy SB; Williamson SK
Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
[TBL] [Abstract][Full Text] [Related]
50. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
51. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration.
Kirichenko AV; Rich TA
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):659-64. PubMed ID: 10348297
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
53. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
54. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
55. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Takeda K; Negoro S; Kudoh S; Okishio K; Masuda N; Takada M; Tanaka M; Nakajima T; Tada T; Fukuoka M
Br J Cancer; 1999 Mar; 79(9-10):1462-7. PubMed ID: 10188891
[TBL] [Abstract][Full Text] [Related]
56. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
[TBL] [Abstract][Full Text] [Related]
58. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
[TBL] [Abstract][Full Text] [Related]
59. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic targets in radiotherapy.
Brown JM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]